SCHEMBL23240239

SCHEMBL23240239

O=C(Nc1ccc(C(F)F)cc1)Oc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.64
MAPT P10636 5/20 0.64
RAD51 Q06609 1/20 0.62
KMT2A Q03164 5/20 0.61
GAA P10253 4/20 0.61
MEN1 O00255 3/20 0.61
LMNA P02545 1/20 0.61
TP53 P04637 1/20 0.61
KDM4E B2RXH2 3/20 0.59
THRB P10828 2/20 0.59
GFER P55789 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
USP2 O75604 1/20 0.56
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
FAAH O00519 6/20 0.51
RAB9A P51151 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8063648 0.86 ALDH1A1 (0.82) ALDH1A1MAPTRAD51KMT2AGAA
SCHEMBL13797610 0.84 ALDH1A1 (0.70) ALDH1A1MAPTRAD51KMT2AGAA
SCHEMBL27692841 0.83 KMT2A (0.62) ALDH1A1MAPTRAD51KMT2AGAA
SCHEMBL12539354 0.83 CYP1A2 (0.61) ALDH1A1MAPTRAD51KMT2AGAA
Phenyl Phenylcarbamate SCHEMBL272994 0.82 ALDH1A1 (0.76) ALDH1A1MAPTRAD51KMT2AGAA
SCHEMBL29739608 0.82 ALDH1A1 (0.57) ALDH1A1MAPTRAD51KMT2AGAA
Phenyl 4-Fluorophenylcarbamate SCHEMBL1892132 0.81 ALDH1A1 (0.70) ALDH1A1MAPTRAD51KMT2AGAA
SCHEMBL6688394 0.81 ALDH1A1 (0.67) ALDH1A1MAPTRAD51KMT2AGAA
Phenyl 4-Fluorophenylcarbamate SCHEMBL27580166 0.80 ALDH1A1 (0.68) ALDH1A1MAPTRAD51KMT2AGAA
SCHEMBL9480551 0.80 ALDH1A1 (0.72) ALDH1A1MAPTRAD51KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 US disclosed
EP-4313047-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS Monte Rosa Therapeutics, Inc. (US) 2024-02-07 EP disclosed
WO-2022200857-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2022-09-29 WO disclosed
EP-4041231-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2022-08-17 EP disclosed
US-20220242846-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-08-04 US disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 ALDH1A1 4150/4885MAPT 4671/4885RAD51 3229/4885
US-20220242846-A1 ISOINDOLINONE COMPOUNDS AOC2, AOC3, INF2 ALDH1A1 1331/4885MAPT 4852/4885RAD51 2593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.